KORU Medical Systems (KRMD) vs Anbio Biotechnology (NNNN)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
KORU Medical Systems (KRMD) has outperformed Anbio Biotechnology (NNNN) over the past year, losing 24.2% versus a loss of 85.1%. Anbio Biotechnology is the larger company by market cap ($202.8 million vs $137.8 million), about 1.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRMD | NNNN |
|---|---|---|
| Share price | $3.00 | $4.62 |
| Market cap | $137.80M | $202.78M |
| 1-day change | +0.67% | -5.71% |
| YTD return | -48.71% | -84.64% |
| 1-year return | -24.17% | -85.09% |
| 5-year return | +3.83% | — |
| P/E ratio (TTM) | — | 30.80 |
| Forward P/E | 85.71 | — |
| EPS (TTM) | $-0.04 | $0.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.61 | $44.73 |
| 52-week low | $2.86 | $4.55 |
| Distance from 52-week high | -54.60% | -89.67% |
| Analyst consensus | none | — |
| Avg. price target upside | +108.33% | — |
| Average volume | 232.65K | 147.21K |
| Shares outstanding | 45.93M | 43.89M |
| Employees | 73 | 27 |
| Sector | Health Care | Health Care |
| Industry | Medical/Dental Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRMD has outperformed NNNN by 60.9 percentage points over the past year.
About KORU Medical Systems
KRMD stock →KORU Medical Systems, Inc. develops, manufactures, and commercializes subcutaneous infusion solutions primarily for the subcutaneous drug delivery market in the United States and internationally.
Health Care · Medical/Dental Instruments · 73 employees
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
KRMD vs NNNN FAQ
Which is bigger, KORU Medical Systems or Anbio Biotechnology?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $202.78M compared with $137.80M for KORU Medical Systems (KRMD).
Which stock has performed better over the past year, KRMD or NNNN?
KRMD returned -24.17% over the past 12 months, compared with -85.09% for NNNN (price return, excluding dividends). Past performance does not predict future results.
Are KORU Medical Systems and Anbio Biotechnology in the same industry?
Both are in the Health Care sector, but in different industries: Medical/Dental Instruments for KORU Medical Systems and Biotechnology: In Vitro & In Vivo Diagnostic Substances for Anbio Biotechnology.